Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Epigenomics AG (ECX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7460
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.

Epigenomics AG (ECX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Epigenomics AG, Medical Equipment, Deal Details 11
Partnerships 11
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16
Equity Offering 17
Epigenomics to Raise Funds Through Rights Offering of Shares 17
Epigenomics Raises USD6.5 Million in Private Placement of Shares 18
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20
Epigenomics Raises USD5.3 Million in Private Placement of Shares 21
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 23
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 24
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 25
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 26
Debt Offering 27
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 28
Acquisition 29
Cathay Fortune International to Acquire Epigenomics 29
Epigenomics AG – Key Competitors 31
Epigenomics AG – Key Employees 32
Epigenomics AG – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 08, 2018: Epigenomics Announces 2018 Second Quarter and Six Month Financial Results 34
May 09, 2018: Epigenomics announces 2018 First Quarter Financial Results 35
Mar 23, 2018: Epigenomics Reports Results for Financial Year 2017 36
Nov 15, 2017: Epigenomics Announces 2017 Third Quarter and Nine Months Financial Results 38
Aug 09, 2017: Epigenomics Announces 2017 Second Quarter and Six Months Financial Results 39
Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 40
May 10, 2017: Epigenomics announces 2017 First Quarter Financial Results 41
Apr 26, 2017: Epigenomics Reports Results for Financial Year 2016 42
Corporate Communications 43
Nov 29, 2017: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand) 43
Nov 08, 2017: Epigenomics Appointment of Director Reimbursement and Medical Affairs 44
Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Epigenomics AG, Medical Equipment, Key Facts, 2017 2
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Deals By Market, 2012 to YTD 2018 9
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16
Epigenomics to Raise Funds Through Rights Offering of Shares 17
Epigenomics Raises USD6.5 Million in Private Placement of Shares 18
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20
Epigenomics Raises USD5.3 Million in Private Placement of Shares 21
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 23
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 24
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 25
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 26
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 28
Cathay Fortune International to Acquire Epigenomics 29
Epigenomics AG, Key Competitors 31
Epigenomics AG, Key Employees 32
Epigenomics AG, Subsidiaries 33

List of Figures
Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mizuho Financial Group Inc:企業のM&A・事業提携・投資動向
    Mizuho Financial Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mizuho Financial Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Sumitomo Mitsui Trust Holdings Inc:企業の戦略・SWOT・財務分析
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Mithra Pharmaceuticals SA (MITRA):医療機器:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • Roust Corporation:企業のM&A・事業提携・投資動向
    Roust Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Roust Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Kadimastem Ltd (KDST):企業の財務・戦略的SWOT分析
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • Qiagen NV (QIA)-医療機器分野:企業M&A・提携分析
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s produc …
  • Amerisafe, Inc.:企業の戦略・SWOT・財務情報
    Amerisafe, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amerisafe, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • R-Biopharm AG-医療機器分野:企業M&A・提携分析
    Summary R-Biopharm AG (R-Biopharm), a subsidiary of Rohm GmbH is a clinical diagnostics center that test solutions for clinical diagnostics and food and feed analysis. The center offers test systems in the areas of infectological stool diagnostics, serological infection and allergy diagnostics for c …
  • Savola Group Co:企業の戦略・SWOT・財務情報
    Savola Group Co - Strategy, SWOT and Corporate Finance Report Summary Savola Group Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Astellas Pharma Inc.:企業の戦略・SWOT・財務情報
    Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report Summary Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myop …
  • Icon Genetics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Icon Genetics GmbH (Icon Genetics), a subsidiary of Denka Co Ltd, is a technology company that offers plant engineering technologies. The company develops, manufactures and markets biopharmaceutical product candidates, engineered organisms and technology platforms for plant biotechnology and …
  • Navigator Holdings Ltd (NVGS):企業の財務・戦略的SWOT分析
    Summary Navigator Holdings Ltd (Navigator) operates as an oil and gas company that offers seaborne transportation of liquefied gases. The company transports ammonia, ethane, ethylene, ambient LPG, petrochemicals and LPG products. It provides fleet management, ship management, gas transportation and …
  • Thermo Fisher Scientific Inc.:企業のM&A・事業提携・投資動向
    Thermo Fisher Scientific Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thermo Fisher Scientific Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Confluent Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Confluent Medical Technologies Inc (CMT), formerly Nitinol Devices and Components Inc is a medical device company that manufactures and markets nitinol devices and balloon catheters. The company provides products such as wire, strip, sheet, tubing and bar, among others. It offers development …
  • Frontage Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Frontage Laboratories Inc (Frontage), a subsidiary of Hangzhou Tigermed Consulting Co Ltd is a contract research organization that offers early phase drug development and other research services. The organization’s services include clinical research, drug metabolism and pharmacokinetic, CMC …
  • Dimerix Bioscience Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Dimerix Bioscience Pty Ltd (Dimerix), a subsidiary of Sun Biomedical Ltd is a biopharmaceutical company that offers drug discovery assays and progressing clinical programs. The company provides product development, discovery services, and others. It provides Receptor-HIT a cell-based assay a …
  • Celsense Inc-製薬・医療分野:企業M&A・提携分析
    Summary Celsense Inc (Celsense) is a biotechnology company that develops magnetic resonance imaging detection products. The company’s products include v-sense, cell sense and voxel tracker. Its v-sense product is used to detect a range of lesions and diseases where inflammation is a hallmark such as …
  • Brigham and Women’s Hospital:企業のM&A・事業提携・投資動向
    Brigham and Women's Hospital - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brigham and Women's Hospital Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • EOS imaging SA (EOSI):医療機器:M&Aディール及び事業提携情報
    Summary EOS imaging SA (EOS Imaging) is an orthopedic imaging company that designs, develops, and markets EOS patented medical imaging system. EOS captures whole body images of a standing patient in a single scan without any stitching or vertical distortion. Through EOS, the company provides the ful …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆